Gilead Sciences has acquired the small Danish biotech EpiTherapeutics for €57M. The epigenetics-expert has generated a library of small molecule inhibitors of gene transcription regulation than can be used for certain cancer treatments.

The American company announced the signing of a definitive agreement to purchase the Danish company for €57M. EpiTherapeutics is developing innovative cancer drugs based on epigenetics, a therapeutic area researched by renowned scientist Professor Kristian Helin and his group at the Biotech Research & Innovation Centre (BRIC) at the University of Copenhagen. The company’s development programs are focused on enzymes involved in the regulation of transcription in cancer. Its lead compounds are still in a pre-clinical phase.

Gilead, who already purchased New Jersey-based Pharmasset in 2011, owes its growth to Pharmasset’s hepatitis C drug. Let’s see if this new acquisition also helps Gilead to beef up its portfolio.

Previous post

Is the Biotech sector facing the issues of the Pharma Industry?

Next post

Omeicos is moving forward with the appointment of D. Ulrich Dauer

Let's Continue The Conversation

Feel free to send us comments about this article to comments@labiotech.eu and/or comment on that article on social media.